CompletedNot Applicable

Assessment of MGMT Promoter Methylation in Advanced Ewing Sarcoma Treated With Temozolomide and Irinotecan

Italy, United Kingdom82 participantsStarted 2014-04-15

Plain-language summary

This is a biological study in patients with advanced Ewing Sarcoma who received, according, clinical practice, temozolomide and irinotecan The O6-methylguanine-DNA methyltransferase (MGMT) methylation status, will be correlated with the disease clinical data and with the disease response

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Histological confirmed diagnosis of Ewing Sarcoma
✓. Chemotherapic treatment with temozolomide and irinotecan
✓. Written informed consent prior to any study related activities

Exclusion criteria

✕. Lack of written informed consent for the study
✕. Any situation that could interfere with the complete data collection of the clinical data related to the temozolomide and irinotecan treatment

What they're measuring

Assessment of MGMT promoter methylation

Timeframe: at day 1

Trial details

NCT IDNCT03542097

SponsorIstituto Ortopedico Rizzoli

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2018-12-31

View on ClinicalTrials.gov More Ewing Sarcoma Family of Tumors trials